Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 196

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein

Open access
Widmer, N., Decosterd, L. A., Csajka, C., Leyvraz, S., Duchosal, M. A., Rosselet, A., Rochat, B., Eap, C. B., Henry, H., Biollaz, J., Buclin, T. · 2006 · British Journal of Clinical Pharmacology

Abstract

Aims: The aims of this observational study were to assess the variability in imatinib pharmacokinetics and to explore the relationship between its disposition and various biological covariates, especially plasma α 1‐acid glycoprotein concentrations. Methods: A population pharmacokinetic analysis was performed using NONMEM based on 321 plasma samples from 59 patients with either chronic myeloid leukaemia or gastrointestinal stromal tumours. The influence of covariates on oral clearance and volume of distribution was examined. Furthermore, the in vivo intracellular pharmacokinetics of imatinib was explored in five patients. Results: A one‐compartment model with first‐order absorption appropriately described the data, giving a mean (± SEM) oral clearance of 14.3 l h−1 (± 1.0) and a volume of distribution of 347 l (± 62). Oral clearance was influenced by body weight, age, sex and disease diagnosis. A large proportion of the interindividual variability (36% of clearance and 63% of volume of distribution) remained unexplained by these demographic covariates. Plasma α 1‐acid glycoprotein concentrations had a marked influence on total imatinib concentrations. Moreover, we observed an intra/extracellular ratio of 8, suggesting substantial uptake of the drug into the target cells. Conclusion: Because of the high pharmacokinetic variability of imatinib and the reported relationships between its plasma concentration and efficacy and toxicity, the usefulness of therapeutic drug monitoring as an aid to optimizing therapy should be further investigated. Ideally, such an approach should take account of either circulating α 1‐acid glycoprotein concentrations or free imatinib concentrations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2006.02719.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 196

Metadata

Authors
Widmer, N., Decosterd, L. A., Csajka, C., Leyvraz, S., Duchosal, M. A., Rosselet, A., Rochat, B., Eap, C. B., Henry, H., Biollaz, J., & Buclin, T.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2006-06-23
Volume
62
Issue
1
Pages
97-112
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2140111850
Cited by
196
References
1
FWCI
8.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein. https://app.cochat.ai/papers/10.1111/j.1365-2125.2006.02719.x
The paper
Widmer, N., Decosterd, L. A., Csajka, C., Leyvraz, S., Duchosal, M. A., Rosselet, A., Rochat, B., Eap, C. B., Henry, H., Biollaz, J., & Buclin, T. (2006). Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2006.02719.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.